Showing 1,701 - 1,720 results of 29,358 for search '(( 50 ((((ppm decrease) OR (nn decrease))) OR (a decrease)) ) OR ( a web decrease ))', query time: 0.81s Refine Results
  1. 1701

    Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

    Published 2022
    “…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
  2. 1702

    Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

    Published 2022
    “…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
  3. 1703

    Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

    Published 2022
    “…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
  4. 1704
  5. 1705

    Table1_Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part I: Genetic... by Veronika Todorovova (12157917)

    Published 2022
    “…Differences were also found in the effects of various APOE isoforms on lipid lowering. A significant decrease in lipid parameters was observed with the E2E2 isoform whereas a minimal decrease was seen with the E4E4 and E3E3 isoforms.…”
  6. 1706

    Image1_Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part I: Genetic... by Veronika Todorovova (12157917)

    Published 2022
    “…Differences were also found in the effects of various APOE isoforms on lipid lowering. A significant decrease in lipid parameters was observed with the E2E2 isoform whereas a minimal decrease was seen with the E4E4 and E3E3 isoforms.…”
  7. 1707
  8. 1708
  9. 1709
  10. 1710
  11. 1711
  12. 1712
  13. 1713
  14. 1714
  15. 1715

    Effect of incubation time on IC<sub>50</sub>s for zanamivir, oseltamivir and peramivir. by Susan Barrett (209202)

    Published 2011
    “…(A) Final higher IC<sub>50</sub> values for binding of zanamivir without preincubation compared to preincubation and the decreases in IC<sub>50</sub>s without preincubation over the 60 min correlate with slow binding. …”
  16. 1716

    Table_4_Clinical Features of 50 Patients With Primary Adrenal Lymphoma.DOCX by Yan Wang (15435)

    Published 2020
    “…<p>Background and Objective: Primary adrenal lymphoma is a rare, progressive, easily misdiagnosed adrenal tumor with a poor prognosis. …”
  17. 1717

    Table_1_Clinical Features of 50 Patients With Primary Adrenal Lymphoma.DOCX by Yan Wang (15435)

    Published 2020
    “…<p>Background and Objective: Primary adrenal lymphoma is a rare, progressive, easily misdiagnosed adrenal tumor with a poor prognosis. …”
  18. 1718

    Table_2_Clinical Features of 50 Patients With Primary Adrenal Lymphoma.DOCX by Yan Wang (15435)

    Published 2020
    “…<p>Background and Objective: Primary adrenal lymphoma is a rare, progressive, easily misdiagnosed adrenal tumor with a poor prognosis. …”
  19. 1719
  20. 1720